|
Post by prcgorman2 on Apr 3, 2019 16:14:04 GMT -5
The title of the thread confuses me. What bleeding? Aren't we trading around where we were before the surprise (and unfortunately timed) dilution.
|
|
|
Post by sportsrancho on Apr 3, 2019 16:58:23 GMT -5
The title of the thread confuses me. What bleeding? Aren't we trading around where we were before the surprise (and unfortunately timed) dilution. Let’s name it we should bleed up!
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 3, 2019 17:00:01 GMT -5
Bigchungus, a few days ago you accused MC of either being incompetent or a crook. Today you're thinking about buying more stock. You're confusing me. Edit:Here is part of what you said "Either 1.) Our CEO lacks the business sense of a 6th grade Junior Achievement member or 2.) he is providing share price depression for friends on the other side. Either way, its not good for shareholders." I think MNKD has a great and potentially revolutionary product. There have been some very obvious mistakes by the leadership, to the point that I am questioning whether they should be removed. This is how investing works, if you have a great product that is being foiled by poor leadership, you make your concerns know to the controlling authority and vote your shares accordingly. I'm in the same boat with Mike K, the product has great potential and can lift the company to financial success, but our leadership is dropping the ball (intentionally or not) and needs to go, or at least have some further separation of power that will prevent him from putting his and his cronies interests above those of the shareholders. He has had his shot and failed. If Afrezza was tracking toward say $45 - $50mm in sales this year, that would demonstrate nice growth over 2018 sales of $17mm and if this hypothetical growth continued in 2020 Afrezza sales would be north of $100mm and the cash burn problem would be in the rear view mirror. Mike is a big company guy and I don't think he is wired for the street fight. DeSisto was and too bad it did not work out. I like Mike but first time I met him in Danbury at the ASM he did not seem to have the grit needed for a startup. He also seemed a bit naive which led me to believe part of his ascent at Amgen was due to relationships vs accomplishments and many times at big companies, that is how it works. Problem now is if you get rid of management, there will be severance packages to pay and how do you recruit capable new talent? If for some reason there was a management change and at the same time a $100mm cash infusion, it would then be possible to get the right people to come in for lower cash comp but massive option rewards so if successful, they could walk away with $25mm +. What Mannkind needs I believe is a powerful partner who may or may not be in the diabetes space but is for sure not in the insulin space. From a strategic financial standpoint, I don't think Afrezza would maximize shareholder value for Lilly or Novo but hey, maybe Mike's strategy is to limp things along until the Peds trial is complete and then the path to success becomes clearer and easier and if that's the case, if no good TS deals its a lot more dilution, RS ...
|
|
|
Post by golfeveryday on Apr 3, 2019 17:23:47 GMT -5
I think MNKD has a great and potentially revolutionary product. There have been some very obvious mistakes by the leadership, to the point that I am questioning whether they should be removed. This is how investing works, if you have a great product that is being foiled by poor leadership, you make your concerns know to the controlling authority and vote your shares accordingly. I'm in the same boat with Mike K, the product has great potential and can lift the company to financial success, but our leadership is dropping the ball (intentionally or not) and needs to go, or at least have some further separation of power that will prevent him from putting his and his cronies interests above those of the shareholders. He has had his shot and failed. If Afrezza was tracking toward say $45 - $50mm in sales this year, that would demonstrate nice growth over 2018 sales of $17mm and if this hypothetical growth continued in 2020 Afrezza sales would be north of $100mm and the cash burn problem would be in the rear view mirror. Mike is a big company guy and I don't think he is wired for the street fight. DeSisto was and too bad it did not work out. I like Mike but first time I met him in Danbury at the ASM he did not seem to have the grit needed for a startup. He also seemed a bit naive which led me to believe part of his ascent at Amgen was due to relationships vs accomplishments and many times at big companies, that is how it works. Problem now is if you get rid of management, there will be severance packages to pay and how do you recruit capable new talent? If for some reason there was a management change and at the same time a $100mm cash infusion, it would then be possible to get the right people to come in for lower cash comp but massive option rewards so if successful, they could walk away with $25mm +. What Mannkind needs I believe is a powerful partner who may or may not be in the diabetes space but is for sure not in the insulin space. From a strategic financial standpoint, I don't think Afrezza would maximize shareholder value for Lilly or Novo but hey, maybe Mike's strategy is to limp things along until the Peds trial is complete and then the path to success becomes clearer and easier and if that's the case, if no good TS deals its a lot more dilution, RS ... they definitely need a partner and I can’t believe there have been no offers. So, mnkd obviously thinks a little too highly of their product and won’t admit they need the help like ASAP
|
|
|
Post by sportsrancho on Apr 3, 2019 17:37:41 GMT -5
Confirmation from Mike: "Hoping [warrants] expire so we don't have dilution!" Spencer is having a meltdown on StockTwits over this😂
|
|
|
Post by falconquest on Apr 3, 2019 17:43:01 GMT -5
He has had his shot and failed. If Afrezza was tracking toward say $45 - $50mm in sales this year, that would demonstrate nice growth over 2018 sales of $17mm and if this hypothetical growth continued in 2020 Afrezza sales would be north of $100mm and the cash burn problem would be in the rear view mirror. Mike is a big company guy and I don't think he is wired for the street fight. DeSisto was and too bad it did not work out. I like Mike but first time I met him in Danbury at the ASM he did not seem to have the grit needed for a startup. He also seemed a bit naive which led me to believe part of his ascent at Amgen was due to relationships vs accomplishments and many times at big companies, that is how it works. Problem now is if you get rid of management, there will be severance packages to pay and how do you recruit capable new talent? If for some reason there was a management change and at the same time a $100mm cash infusion, it would then be possible to get the right people to come in for lower cash comp but massive option rewards so if successful, they could walk away with $25mm +. What Mannkind needs I believe is a powerful partner who may or may not be in the diabetes space but is for sure not in the insulin space. From a strategic financial standpoint, I don't think Afrezza would maximize shareholder value for Lilly or Novo but hey, maybe Mike's strategy is to limp things along until the Peds trial is complete and then the path to success becomes clearer and easier and if that's the case, if no good TS deals its a lot more dilution, RS ... they definitely need a partner and I can’t believe there have been no offers. So, mnkd obviously thinks a little too highly of their product and won’t admit they need the help like ASAP I'll let you in on a secret. I was told by a source close to the family that Mannkind had this great new diabetes drug that was inhaled instead of injected and they were looking to partner which would skyrocket the share price............at $19.00! They have been begging for a partner ever since. (we'll just leave Sanofi out of the picture since that wasn't really a partnership).
Don't you recall Hakan begging for people to contact him about partnerships at a quarterly conference call? It was rather pathetic. My point is, they have not been able to partner with anyone for 20 years. I don't see it happening now. Any BP could take over this company in a heartbeat so obviously no one sees value here. Unfortunately that's the state of affairs like it or not and why making Afrezza successful is so important.
|
|
|
Post by agedhippie on Apr 3, 2019 17:48:25 GMT -5
Confirmation from Mike: "Hoping [warrants] expire so we don't have dilution!" Spencer is having a meltdown on StockTwits over this😂 Thanks. I am going to break the habits of a lifetime and go and watch. Pass the popcorn...
|
|
|
Post by sportsrancho on Apr 3, 2019 17:50:15 GMT -5
Spencer is having a meltdown on StockTwits over this😂 Thanks. I am going to break the habits of a lifetime and go and watch. Pass the popcorn... stocktwits.com/x1spencer
|
|
|
Post by mnholdem on Apr 3, 2019 17:53:13 GMT -5
Confirmation from Mike: "Hoping [warrants] expire so we don't have dilution!" Spencer is having a meltdown on StockTwits over this😂 SO is all about the money. Very one dimensional, IMO.
|
|
|
Post by bigchungus91354 on Apr 3, 2019 18:10:45 GMT -5
I think MNKD has a great and potentially revolutionary product. There have been some very obvious mistakes by the leadership, to the point that I am questioning whether they should be removed. This is how investing works, if you have a great product that is being foiled by poor leadership, you make your concerns know to the controlling authority and vote your shares accordingly. I'm in the same boat with Mike K, the product has great potential and can lift the company to financial success, but our leadership is dropping the ball (intentionally or not) and needs to go, or at least have some further separation of power that will prevent him from putting his and his cronies interests above those of the shareholders. He has had his shot and failed. If Afrezza was tracking toward say $45 - $50mm in sales this year, that would demonstrate nice growth over 2018 sales of $17mm and if this hypothetical growth continued in 2020 Afrezza sales would be north of $100mm and the cash burn problem would be in the rear view mirror. Mike is a big company guy and I don't think he is wired for the street fight. DeSisto was and too bad it did not work out. I like Mike but first time I met him in Danbury at the ASM he did not seem to have the grit needed for a startup. He also seemed a bit naive which led me to believe part of his ascent at Amgen was due to relationships vs accomplishments and many times at big companies, that is how it works. Problem now is if you get rid of management, there will be severance packages to pay and how do you recruit capable new talent? If for some reason there was a management change and at the same time a $100mm cash infusion, it would then be possible to get the right people to come in for lower cash comp but massive option rewards so if successful, they could walk away with $25mm +. What Mannkind needs I believe is a powerful partner who may or may not be in the diabetes space but is for sure not in the insulin space. From a strategic financial standpoint, I don't think Afrezza would maximize shareholder value for Lilly or Novo but hey, maybe Mike's strategy is to limp things along until the Peds trial is complete and then the path to success becomes clearer and easier and if that's the case, if no good TS deals its a lot more dilution, RS ... Amen! Partner would save the day. Unfortunately, every week of poor sales gives MNKD a little less leverage.
|
|
|
Post by ilovekauai on Apr 3, 2019 18:14:04 GMT -5
Until this all gets sorted out, no bonuses, no raises, no more Hawaii for upper management staff. Nada. And, I'm still steamed about the ASM being moved to NYC this year, at a swanky hotel, instead of at corporate headquarters in Thousand Oaks, CA where it should always be held w/o any hesitation or venue move. I feel disenfranchised and will not be traveling to NYC. Nice move to avoid distraught shareholders asking pointed questions? You be the judge. Thank you.
|
|
|
Post by uvula on Apr 3, 2019 18:47:36 GMT -5
I'm not sure if I want a new CEO or not, but I would rather sell the whole company than risk another new CEO at mnkd.
|
|
|
Post by boca1girl on Apr 3, 2019 18:52:50 GMT -5
Until this all gets sorted out, no bonuses, no raises, no more Hawaii for upper management staff. Nada. And, I'm still steamed about the ASM being moved to NYC this year, at a swanky hotel, instead of at corporate headquarters in Thousand Oaks, CA where it should always be held w/o any hesitation or venue move. I feel disenfranchised and will not be traveling to NYC. Nice move to avoid distraught shareholders asking pointed questions? You be the judge. Thank you. There are shareholders on the East coast too. The fair thing is to alternate between HQ and Danbury. I too am disappointed the ASM is in NYC and not Danbury.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 3, 2019 19:38:32 GMT -5
He has had his shot and failed. If Afrezza was tracking toward say $45 - $50mm in sales this year, that would demonstrate nice growth over 2018 sales of $17mm and if this hypothetical growth continued in 2020 Afrezza sales would be north of $100mm and the cash burn problem would be in the rear view mirror. Mike is a big company guy and I don't think he is wired for the street fight. DeSisto was and too bad it did not work out. I like Mike but first time I met him in Danbury at the ASM he did not seem to have the grit needed for a startup. He also seemed a bit naive which led me to believe part of his ascent at Amgen was due to relationships vs accomplishments and many times at big companies, that is how it works. Problem now is if you get rid of management, there will be severance packages to pay and how do you recruit capable new talent? If for some reason there was a management change and at the same time a $100mm cash infusion, it would then be possible to get the right people to come in for lower cash comp but massive option rewards so if successful, they could walk away with $25mm +. What Mannkind needs I believe is a powerful partner who may or may not be in the diabetes space but is for sure not in the insulin space. From a strategic financial standpoint, I don't think Afrezza would maximize shareholder value for Lilly or Novo but hey, maybe Mike's strategy is to limp things along until the Peds trial is complete and then the path to success becomes clearer and easier and if that's the case, if no good TS deals its a lot more dilution, RS ... they definitely need a partner and I can’t believe there have been no offers. So, mnkd obviously thinks a little too highly of their product and won’t admit they need the help like ASAP Hard to say what if any offers they have received. Never really know what goes on behind closed doors.
|
|
|
Post by lifebreath on Apr 3, 2019 21:48:50 GMT -5
I think MNKD has a great and potentially revolutionary product. There have been some very obvious mistakes by the leadership, to the point that I am questioning whether they should be removed. This is how investing works, if you have a great product that is being foiled by poor leadership, you make your concerns know to the controlling authority and vote your shares accordingly. I'm in the same boat with Mike K, the product has great potential and can lift the company to financial success, but our leadership is dropping the ball (intentionally or not) and needs to go, or at least have some further separation of power that will prevent him from putting his and his cronies interests above those of the shareholders. He has had his shot and failed. If Afrezza was tracking toward say $45 - $50mm in sales this year, that would demonstrate nice growth over 2018 sales of $17mm and if this hypothetical growth continued in 2020 Afrezza sales would be north of $100mm and the cash burn problem would be in the rear view mirror. Mike is a big company guy and I don't think he is wired for the street fight. DeSisto was and too bad it did not work out. I like Mike but first time I met him in Danbury at the ASM he did not seem to have the grit needed for a startup. He also seemed a bit naive which led me to believe part of his ascent at Amgen was due to relationships vs accomplishments and many times at big companies, that is how it works. Problem now is if you get rid of management, there will be severance packages to pay and how do you recruit capable new talent? If for some reason there was a management change and at the same time a $100mm cash infusion, it would then be possible to get the right people to come in for lower cash comp but massive option rewards so if successful, they could walk away with $25mm +. What Mannkind needs I believe is a powerful partner who may or may not be in the diabetes space but is for sure not in the insulin space. From a strategic financial standpoint, I don't think Afrezza would maximize shareholder value for Lilly or Novo but hey, maybe Mike's strategy is to limp things along until the Peds trial is complete and then the path to success becomes clearer and easier and if that's the case, if no good TS deals its a lot more dilution, RS ... He had his shot and failed is the perfect summation of the Castagna reign. I would think he could be replaced without a complete housecleaning. Which would leave MNKD with only Castagnas compensation package to pay. I do believe the management team assembled would preform at a much higher level without Castagna. I really hope Kresa is still cogniscent enough to realize the Castagna experiment has failed. The sooner he is replaced the better chance true Longs have of recouping our 90% plus losses
|
|